Loading…
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-87M | $-90M | $-78M | -34.1% | -100.0% | 20.2% |
| 2024 | $1M | $-72M | $-75M | $-71M | -24.2% | - | 106.9% |
| 2023 | $0M | $-33M | $-36M | $-52M | -19.5% | - | -34.2% |
| 2022 | $0M | $-52M | $-55M | $-55M | 37.9% | - | - |
| 2021 | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0.92 | 0 |
| Operating Revenue | - | 0 | 0 | 0.92 | 0 |
| Operating Expense | - | 56.52 | 55.58 | 83.53 | 103.33 |
| Research And Development | - | 47.50 | 44.39 | 60.92 | 75.01 |
| Selling General And Administration | - | 9.01 | 11.19 | 22.61 | 28.32 |
| Total Expenses | - | 56.52 | 55.58 | 83.53 | 103.33 |
| Operating Income | - | -56.52 | -55.58 | -82.60 | -103.33 |
| Total Operating Income As Reported | - | -56.52 | -55.58 | -82.60 | -103.33 |
| EBITDA | - | -51.99 | -33.01 | -71.89 | -87.25 |
| Normalized EBITDA | - | -51.99 | -49.36 | -71.89 | -87.25 |
| EBIT | - | -55.19 | -36.30 | -75.13 | -90.35 |
| Interest Income | - | 1.34 | 2.95 | 8.47 | 11.55 |
| Interest Expense | - | 0 | 0.01 | 0.01 | 0 |
| Net Interest Income | - | 1.34 | 2.94 | 8.46 | 11.54 |
| Other Non Operating Income Expenses | - | -0.01 | -0.03 | -0.99 | 1.44 |
| Other Income Expense | - | -0.01 | 16.33 | -0.99 | 1.44 |
| Interest Income Non Operating | - | 1.34 | 2.95 | 8.47 | 11.55 |
| Interest Expense Non Operating | - | 0 | 0.01 | 0.01 | 0 |
| Net Non Operating Interest Income Expense | - | 1.34 | 2.94 | 8.46 | 11.54 |
| Pretax Income | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income From Continuing And Discontinued Operation | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income From Continuing Operation Net Minority Interest | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income Common Stockholders | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Net Income Including Noncontrolling Interests | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Normalized Income | - | -55.19 | -52.67 | -75.14 | -90.35 |
| Diluted NI Availto Com Stockholders | - | -55.19 | -36.32 | -75.14 | -90.35 |
| Basic Average Shares | 1.46 | 1.46 | 0.49 | 17.57 | - |
| Diluted Average Shares | 1.46 | 1.46 | 4.66 | 17.57 | - |
| Reconciled Depreciation | - | 3.20 | 3.30 | 3.25 | 3.09 |
| Total Unusual Items | - | 0 | 16.36 | 0.57 | - |
| Total Unusual Items Excluding Goodwill | - | 0 | 16.36 | 0.57 | - |
| Special Income Charges | - | 0 | 16.36 | 0.57 | - |
| Restructuring And Mergern Acquisition | - | 0 | -16.36 | -0.57 | - |
| General And Administrative Expense | - | 9.01 | 11.19 | 22.61 | 28.32 |
| Other Gand A | - | 9.01 | 11.19 | 10.70 | 11.35 |
| Salaries And Wages | - | - | - | 11.91 | 16.97 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Neurogene Inc.this co. | NGNE | $434M | -4.81 | 1.64 | -34.1% | -3.91 |
| NRC Health | NRC | $445M | 38.37 | 31.82 | 82.9% | 17.20 |
| Myriad Genetics, Inc. | MYGN | $443M | -1.21 | 1.20 | -99.4% | -1.52 |
| Varex Imaging Corporation | VREX | $441M | - | 0.93 | -14.9% | 973.79 |
| Emergent BioSolutions Inc. | EBS | $435M | 8.28 |
| - |
| - |
| - |
| 0.83 |
| 10.1% |
| 3.37 |
| Evolus, Inc. | EOLS | $435M | -8.42 | -18.81 | 223.5% | -23.79 |
| Rezolute, Inc. | RZLT | $434M | -5.84 | 2.68 | -45.9% | -4.28 |
| ClearPoint Neuro, Inc. | CLPT | $429M | -16.81 | 15.33 | -91.1% | -21.18 |
| Orthofix Medical Inc. | OFIX | $418M | -4.53 | 0.93 | -20.5% | 51.78 |
| Peer Median | - | -4.53 | 1.07 | -17.7% | 0.93 | |